ストックスクリーナーアプリを入手
11.20
10.13%
1.03
プレマーケット:
11.16
-0.04
-0.36%
前日終値:
$10.17
開ける：
$10.22
24時間の取引高:
11.93M
Relative Volume:
1.24
時価総額：
$13.06B
収益：
$14.33B
当期純損益:
$-3.79B
株価収益率:
-3.5331
EPS:
-3.17
ネットキャッシュフロー:
$1.84B
1週間 パフォーマンス:
+6.77%
1か月 パフォーマンス:
+14.99%
6か月 パフォーマンス:
+27.71%
1年 パフォーマンス:
-14.44%
1日の値動き範囲:
$10.22
$11.28
1週間の範囲:
$9.92
$11.28
52週間の値動き範囲:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
VTRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
11.20 | 11.71B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
120.12 | 52.79B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.01 | 43.31B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.85 | 42.61B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
25.13 | 27.83B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
459.21 | 19.54B | 3.08B | 1.24B | 1.07B | 25.61 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-06-06 | 開始されました | Goldman | Neutral |
| 2024-07-19 | 再開されました | Jefferies | Buy |
| 2023-10-23 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-06-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2023-04-24 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-02-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-10 | アップグレード | UBS | Sell → Neutral |
| 2022-11-08 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 再開されました | Jefferies | Hold |
| 2022-06-14 | 開始されました | UBS | Sell |
| 2022-05-10 | ダウングレード | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 開始されました | Citigroup | Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2021-03-02 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-02-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 開始されました | Argus | Hold |
| 2020-12-14 | 開始されました | Bernstein | Mkt Perform |
すべてを表示
Viatris Inc (VTRS) 最新ニュース
Will Viatris Inc. (VIA) stock benefit from commodity supercycleJuly 2025 WrapUp & Fast Gain Stock Tips - newser.com
What dividend safety score for Viatris Inc. stock2025 Breakouts & Breakdowns & Consistent Profit Alerts - newser.com
Can Viatris Inc. (VIA) stock surprise markets with earningsPrice Action & Weekly Market Pulse Alerts - newser.com
Is it time to cut losses on Viatris Inc.2025 Top Gainers & Technical Pattern Based Signals - newser.com
Viatris Inc. stock rises Tuesday, outperforms market - MSN
Evaluating Viatris (VTRS) Valuation After Strong Q3 Results and Upbeat 2025 Guidance - simplywall.st
What drives Viatris Inc VIA stock priceChart Pattern Recognition & Small Budget Investment Tips - earlytimes.in
U.S. Markets Finished Mixed Tuesday As Viatris Led, CoreWeave Lagged - Barron's
Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know - Yahoo Finance
What technical charts say about Viatris Inc. stock2025 AllTime Highs & Safe Capital Growth Trade Ideas - newser.com
Viatris at UBS Global Healthcare Conference: Strategic Growth Initiatives - Investing.com India
Pulmonary Arterial Hypertension Market Research Report 2025, Competitive Analysis of Gilead Sciences, Viatris, Sandoz, J&J, Sun Pharma, Lupin Pharma, GlaxoSmithKline, Bayer, United Therapeutics - Yahoo Finance
Is now a turning point for Viatris Inc.Trade Volume Summary & Consistent Profit Alerts - newser.com
Will Viatris Inc. stock return to pre crisis levelsJuly 2025 Spike Watch & Risk Controlled Daily Trade Plans - newser.com
What is the fair value estimate for Viatris Inc. (VIA) stock in 2025Rate Cut & Free High Return Stock Watch Alerts - newser.com
Type 2 Diabetes MarketSee Which Drugs Are Leading in 2025Novo - openPR.com
Viatris’ Indore Plant Remediation ‘Largely Complete’ As FDA Re-Inspection Looms - Citeline News & Insights
Is Viatris Inc. stock a good choice for value investors2025 Major Catalysts & Accurate Technical Buy Alerts - newser.com
Will Viatris Inc. stock recover faster than peers2025 Key Lessons & Capital Efficiency Focused Strategies - newser.com
Using AI based signals to follow Viatris Inc.Weekly Gains Summary & Breakout Confirmation Trade Signals - newser.com
Viatris Inc. stock outlook for YEARPortfolio Risk Summary & Weekly Breakout Watchlists - newser.com
How (VTRS) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
What does recent volatility data suggest for Viatris Inc.Earnings Beat & Target Return Focused Stock Picks - newser.com
How Upgraded Guidance and Capital Returns at Viatris (VTRS) Have Changed Its Investment Story - Yahoo Finance
Why Viatris Inc. stock could be next big winnerWeekly Market Report & Technical Pattern Based Signals - newser.com
Viatris Inc. (NASDAQ:VTRS) Q3 2025 Earnings Call Transcript - Insider Monkey
Viatris Nears Completion Of Company-Wide Strategic Review - Citeline News & Insights
Viatris: Q3 Earnings Snapshot - ctinsider.com
Viatris Q3 2025 presentation slides: Raises full-year guidance despite GAAP losses - Investing.com Nigeria
Viatris Lifts Forecasts After Branded Drug Sales Outpace Estimates - Finimize
Viatris Inc. Reports Steady Q3 2025 Performance - TipRanks
Viatris, Inc. Earnings Call: Mixed Sentiment and Strategic Focus - TipRanks
3rd Circ. Won't Revive Investors' Suit Over Viatris Sale - Law360
Viatris (VTRS) Q3 2025 Earnings Call Transcript - Fortune
Viatris Inc (VTRS) Q3 2025 Earnings Call Highlights: Navigating Challenges and Seizing Growth ... By GuruFocus - Investing.com Canada
Can volume confirm reversal in Viatris Inc.Trade Analysis Report & Expert Approved Momentum Ideas - newser.com
Viatris Outpaces Expectations And Lifts Guidance After New Deal - Finimize
Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs - MSN
Viatris Q3 2025 presentation slides: Raises full-year guidance despite GAAP losses By Investing.com - Investing.com South Africa
Earnings call transcript: Viatris Q3 2025 beats earnings expectations, stock dips - Investing.com India
Needle-Free Devices, Technologies and Global Markets - GlobeNewswire
Needle-Free Devices, Technologies and Global Markets (2025-2030) Featuring Profiles of GSK, Novartis, Viatris, PharmaJet and Other Key Players - Yahoo Finance
Viatris Inc (VTRS) 財務データ
収益
当期純利益
現金流量
EPS
2.14%
1.82%
大文字化:
|
ボリューム (24 時間):